NTX 472
Alternative Names: NTX-472Latest Information Update: 11 Jun 2024
At a glance
- Originator Nutcracker Therapeutics
- Class Antineoplastics; Recombinant fusion proteins; RNA; Trispecific antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD47 antigen inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical B-cell lymphoma
Most Recent Events
- 11 Jun 2024 Pharmacodynamics data from a Preclinical trial in B-cell lymphoma released by Nutcracker Therapeutics
- 31 May 2024 Pharmacodynamics data from the preclinical trials in B-cell lymphoma presented at the 60th Annual Meeting of the American Society of Clinical Oncology 2024 (ASCO-2024 (3863589)
- 15 May 2024 Preclinical trials in B-cell lymphoma in USA (IV) prior to May 2024